Indian drugmaker Dr Reddy’s Laboratories Ltd . is planning to launch a generic version of Novo Nordisk A/S ’s Ozempic in March after the drug’s patent expiry, becoming one of the first firms to capture the gold rush for the therapy in the South Asian country. Dr Reddy’s will sell at “competitive pricing” to ensure affordability, M. V. Ramana , its chief executive officer for Branded Markets, told ...
Indian drugmaker Dr Reddy’s Laboratories Ltd . is planning to launch a generic version of Novo Nordisk A/S ’s Ozempic in March after the drug’s patent expiry, becoming one of the first firms to capture the gold rush for the therapy in the South Asian country. Dr Reddy’s will sell at “competitive pricing” to ensure affordability, M. V. Ramana , its chief executive officer for Branded Markets, told reporters Wednesday. The pricing will also depend on how peers price their product. “This would be a major opportunity,” Ramana said. Dr Reddy’s launch of generic Ozempic, used to treat type-2 diabetes, marks the onset of an influx of global competition that Novo Nordisk is expecting for its $30 billion franchise. Dozens of manufacturers in India and other parts of the world have geared up to sell unbranded versions for populations that previously had limited access to the blockbuster drug. Generic semaglutide — the key ingredient in Novo Nordisk’s Ozempic and Wegovy — could be priced as low as $40 in 2026, according to Nomura analyst Saion Mukherjee , less than half the current price of Ozempic in India. Read More: Generic Ozempic Makers Are Coming to Upend the Obesity Market Dr Reddy’s is preparing to manufacture 12 million pens in the first year of sales, Chief Executive Officer Erez Israeli said, adding that it will be making the active ingredient in the drug. It will also partner with other companies in India to market the drug. The patent in India expires on March 21, making it a key market in the firm’s strategy. Other key markets are Turkey, Brazil and Canada, he said. Dr Reddy’s has received marketing approval and manufacturing approval from the Drugs Controller General of India for generic Ozempic, while it is awaiting a marketing nod for its non-branded version of Wegovy, Novo Nordisk’s weight-loss drug. The company is awaiting further guidance from Health Canada after it filed a response in November to a notice of non-compliance , which showed the drug doesn’t m...
REAL ESTATE NEWSLETTER This is an edition of the Real Estate newsletter, a weekly briefing of the biggest commercial deals, news, analysis and trends in office, multifamily, retail and other commercial sectors.
REAL ESTATE NEWSLETTER This is an edition of the Real Estate newsletter, a weekly briefing of the biggest commercial deals, news, analysis and trends in office, multifamily, retail and other commercial sectors.
Nuclear Stocks Surge After Trump Tells Davos "US Going Heavy Into Nuclear" President Trump opened his speech at Davos with a major plug for the US nuclear industry. Trump: "The US is going heavy into nuclear. I wasn't a fan of nuclear, but the safety progress they've made with nuclear is unbelievable. We are very much into the world of nuclear energy" — zerohedge (@zerohedge) January 21, 2026 Nucl...
Nuclear Stocks Surge After Trump Tells Davos "US Going Heavy Into Nuclear" President Trump opened his speech at Davos with a major plug for the US nuclear industry. Trump: "The US is going heavy into nuclear. I wasn't a fan of nuclear, but the safety progress they've made with nuclear is unbelievable. We are very much into the world of nuclear energy" — zerohedge (@zerohedge) January 21, 2026 Nuclear fuel chain and reactor developer stocks spiked in the premarket on Trump‘s comments. The US nuclear industry has suffered decades of atrophy under the crushing weight of nuclear disaster fears, cheap natural gas, crushing regulation hurdles and brutal lawfare from environmental (spoken “anti-nuclear”) activists. But thanks to the unprecedented support from the current federal administration, in particular from Energy Secretary Chris Wright, nuclear is finally “cool” again. As we’ve covered dozens of times over just the past few months, the current administration is taking an all hands-on deck approach for reinvigorating the nuclear industry. *BESSENT: U.S. IS BEHIND CHINA ON NUCLEAR POWER BUT WILL CATCH UP *BESSENT: IT'S ALL HANDS ON DECK FOR NUCLEAR POWER — zerohedge (@zerohedge) October 30, 2025 The US government has recognized the deficit at every stage of the nuclear industry from the lack of domestic uranium mining, the devoid enrichment capacity, the lack of heavy manufacturing and fabrication, and the absence of advanced reactor development. The industry has thankfully received waves of support from the government in the form of awards for enrichment , high speed licensing pathways , and new potential nuclear applications, including launching reactors into space for moon colonization. There’s even more bullish events on the horizon, as we detailed the near term catalyst for the nuclear fuel chain participants with the DOJ granting antitrust immunity for participants willing to revitalize domestic capabilities. Hundreds of billions of dollars have also been predes...
Two deadly crashes in almost as many days have inflicted grief, anger and disruption. Two deadly crashes in almost as many days inflict grief, anger and disruption in Spain.
Two deadly crashes in almost as many days have inflicted grief, anger and disruption. Two deadly crashes in almost as many days inflict grief, anger and disruption in Spain.